Canaccord Genuity Initiates Coverage On Arcturus Therapeutics with Buy Rating
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem has initiated coverage on Arcturus Therapeutics (NASDAQ:ARCT) with a Buy rating.
December 13, 2023 | 9:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity analyst Whitney Ijem has initiated coverage on Arcturus Therapeutics with a Buy rating, indicating a positive outlook for the stock.
Initiation of coverage by an analyst typically signals confidence in the company's future performance and can lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100